BMO Capital Weighs in on Tesaro (TSRO) Following Abstracts at AACR

BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $69 price target on Tesaro (NASDAQ: TSRO) after abstracts were released for the American Association of Cancer Research meeting, which is being convened in Philadelphia, April 18-22. TSRO and partner AnaptysBio will present data for both mouse and human IO antibodies targeting PD-1, TIM-3 and LAG-3.

Birchenough's view:

• These data continue to support TSRO’s investment in the AnaptysBio portfolio of PD-1, LAG-3 and TIM-3 antibodies.
• TSRO expects to file an IND for TSR-042, an anti-PD-1 MAb by year-end 2015, with INDs for a LAG-3, TIM-3, and bispecific PD-1/LAG-3 and PD-1/TIM-3 following every 1-2 quarters.
• TSRO’s other oncology assets such as PARP inhibitor niraparib or ALK/TRK inhibitor TSR-011 could be evaluated with one or more of the IO antibodies.

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $60.63 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Tyler Tech (TYL) PT Raised to $500 at Oppenheimer
• Keurig Dr Pepper (KDP) PT Raised to $39 at Jefferies